EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study

Mamatha Pasnoor, Vera Bril iD, Todd Levine, Jaya Trivedi, Nicholas J Silvestri, Milind Phadnis, Hans D Katzberg, David S Saperstein, Gil I Wolfe, Laura Herbelin, Kiley Higgs, Andrew J Heim und 3 weitere

European Journal of Neurology · 2023

DOI: 10.1111/ene.15745 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Mamatha Pasnoor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Myasthenia Gravis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Data on maintenance therapy with subcutaneous immunoglobulin (SCIg) in myasthenia gravis (MG) are limited. We report on transitioning acetylcholine receptor (AChR) antibody‐positive (Ab+) MG patients on stable intravenous immunoglobulin (IVIg) regimens as part of routine clinical care to SCIg 1:1.2.

Methods

This multicenter North American open‐label prospective investigator‐initiated study had two components: the IVIg Stabilization Period (ISP) enrolling patients already on IVIg as part of routine clinical care (Weeks −10 to −1), followed by transition of stable MG subjects to SCIg in the Experimental Treatment Period (ETP; Weeks 0 to 12). We hypothesized that >65% of patients entering the ETP would have a stable Quantitative Myasthenia Gravis (QMG) score from Week 0 to Week 12. Secondary outcome measures included other efficacy measures, safety, tolerability, IgG levels, and treatment satisfaction.

Results

We recruited 23 patients in the ISP, and 22 entered the ETP. A total of 12 subjects (54.5%) were female, and 18 (81.8%) were White, with mean age 51.4 ± 17 years. We obtained Week 12 ETP QMG data on 19 of 22; one subject withdrew from ETP owing to clinical deterioration, and two subjects withdrew due to dislike of needles. On primary analysis, 19 of 22 participants (86.4%, 95% confidence interval = 0.72–1.00) were treatment successes using last observation carried forward ( p = 0.018). Secondary efficacy measures supported MG stability. SCIg was safe and well tolerated, and IgG levels were stable. Treatment satisfaction was comparable between ISP and ETP.

Conclusions

MG patients on IVIg as part of their routine clinical care remained stable on monthly IVIg dosage, and most maintained similar disease stability on SCIg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousMyasthenia GravisHumansFemaleAdultMiddle AgedAgedMaleProspective StudiesReceptors, CholinergicAutoantibodies

Stichwörter der Autor:innen

Quantitative Myasthenia Gravis scoreefficacyintravenous immunoglobulinmyasthenia gravissubcutaneous immunoglobulin

Substanzen

Immunoglobulins, IntravenousReceptors, CholinergicAutoantibodies

Autor:innen und Institutionen

  • Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • HonorHealth Neurology, Phoenix, Arizona, USA.
  • Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Neurology, University at Buffalo, Buffalo, New York, USA.
  • Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas, USA.

ORCID-Profile: Vera Bril, Mazen M Dimachkie

Förderung

  • CSL Behring

Zitieren

APA

Pasnoor, M., Bril, V., Levine, T., Trivedi, J., Silvestri, N. J., Phadnis, M., Katzberg, H. D., Saperstein, D. S., Wolfe, G. I., Herbelin, L., Higgs, K., Heim, A. J., Statland, J. M., Barohn, R. J., & Dimachkie, M. M. (2023). Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study. European Journal of Neurology. https://doi.org/10.1111/ene.15745

Vancouver

Pasnoor M, Bril V, Levine T, Trivedi J, Silvestri NJ, Phadnis M, et al. Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study. European Journal of Neurology. 2023. doi:10.1111/ene.15745

BibTeX
@article{Pasnoor2023,
  author = {Pasnoor, Mamatha and Bril, Vera and Levine, Todd and Trivedi, Jaya and Silvestri, Nicholas J and Phadnis, Milind and Katzberg, Hans D and Saperstein, David S and Wolfe, Gil I and Herbelin, Laura and Higgs, Kiley and Heim, Andrew J and Statland, Jeffrey M and Barohn, Richard J and Dimachkie, Mazen M},
  title = {Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15745}
}
Kostenlos starten →